Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05689450

Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder

Conditions: Febrile Neutropenia (FN)

Sex: All

Ages: 18 Years – N/A

Enrollment: 50

Sponsor: University Hospital, Basel, Switzerland

Location: Switzerland

Summary

The present trial is a single center, prospective, observational pharmacokinetics and pharmacodynamics (PKPD) cohort study investigating whether patients suffering from a hematological disorder and treated with amikacin due to febrile neutropenia (FN) achieve the predefined amikacin target concentration (Cmax ≥60 mg/L).

Eligibility Criteria

Inclusion Criteria:Age ≥ 18 yearsInformed consent (IC) as documented by signatureDocumented hematological disorderHospitalization at the USB due to the treatment for a hematological disorder (e.g. chemotherapy, stem cell transplantation)Being at risk of developing FN during the hospital stay (e.g. because of chemotherapy)Exclusion Criteria:Previous enrolment into the current studyOutpatientsPatients undergoing hemodialysisWomen who are pregnant (special pharmacokinetic)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05689450). StuddyBuddy aggregates publicly available trial information.